Search clinical trials for: Apatinib plus S-1

Total 1124 results

Zhejiang Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer

Gastric Cancer

China
Changzhou Cancer Hospital of Soochow University

Completed

An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer (EASE)

Non-small Cell Lung Cancer

China
Hebei Medical University Fourth Hospital

Unknown

A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma

Refractory or Metastatic Esophageal Squamous Cell Carcinoma

China
Sun Yat-sen University

Unknown

Compare S-1 Plus Oxaliplatin to S-1 as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer (CAPITAL)

Gastric Cancer

China
Taiho Pharmaceutical Co., Ltd.

Completed

Study of S-1, S-1/CDDP, and 5-FU/CDDP for Advanced Gastric Cancer

Gastric Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer (RESCUE-GC)

Gastric Cancer

China
Fudan University

Terminated

SOX as Salvage Treatment in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Tianjin Medical University Cancer Institute and...

Unknown

Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer

Small Cell Lung Cancer

China
Kyungpook National University Hospital

Unknown

S-1 Versus S-1 Plus Cisplatin as an Adjuvant Chemotherapy to Treat Gastric Cancer

Gastric Cancer

Korea, Republic of
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer

Colorectal Cancer

China
Beijing Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric Cancer

HER-2 Negatived Gastric Cancer

China
Xijing Hospital

Unknown

Study of DPD for Predicting Efficacy and Safety to S-1 Plus Oxaliplatin in Gastrointestinal Cancer

Gastrointestinal Cancer

China
Ruijin Hospital

Active, not recruiting

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

China
Mianyang Central Hospital

Unknown

S-1 IMRT Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Chinese PLA General Hospital

Unknown

The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer

Gastric Cancer

China
Sun Yat-sen University
Guangdong Provincial Hospital of Traditional Chinese Medicine; Guangdong Provincial...

Active, not recruiting

PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer

Colorectal Cancer | Microsatellite Instability High

China
Beijing Friendship Hospital

Completed

Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer

Gastric Cancer
Taiho Pharmaceutical Co., Ltd.
Yakult Honsha Co., LTD

Completed

Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer (SOLAR)

Gastric Cancer

Japan, Korea, Republic of
Yonsei University

Terminated

A Phase II Trial of Adjuvant Chemotherapy With S-1 Plus Oxaliplatin for Locally Advanced Gastric Cancer

Advanced Gastric Cancer

Korea, Republic of
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate

Leukemia

United States
Fujian Cancer Hospital

Recruiting

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Immunotherapy Gastrict Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma

Sarcoma

China
Lei Li

Completed

First-line Chemotherapy for Recurrent Cervical Cancer

Chemotherapy | Recurrent Cervical Carcinoma | Apatinib | Targeted Therapy | Persistent Advanced Cervical Carcinoma | Vascular Endothelial Growth Factor 2 Inhibitor

China
Zhejiang University

Recruiting

Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1 (TACTIC)

Locally Advanced Gastric Carcinoma

China
Peking University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Gastric Cancer

China
China International Medical Foundation
Chinese Society of Clinical Oncology

Unknown

Apatinib Combined With S-1 for the Treatment of Recurrent/Metastatic Head and Neck Malignancies (Y-HR2017-025)

Head and Neck Cancer

China
Changzhou No.2 People's Hospital

Unknown

Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer (ASPC)

Advanced Pancreatic Cancer
Shandong University
The Affiliated Hospital of Qingdao University; Qianfoshan Hospital; The Second...

Recruiting

Antineoplastic Drugs in Elderly Patients

Cancer

China
Tongji Hospital
The Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaborators

Recruiting

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma (CCGLC-008)

Hepatocellular Carcinoma Non-resectable

China
Peking Union Medical College Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia

Gestational Trophoblastic Neoplasia

China
Qingdao Municipal Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer

Gastric Cancer
Hebei Medical University

Not yet recruiting

A Study of HIPEC Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

Gastric Cancer
Tomoshi Tsuchiya

Completed

A Feasibility Study of Oral Adjuvant Chemotherapy With S-1

Non-small Cell Lung Cancer

Japan
Wan-Guang Zhang
The Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaborators

Recruiting

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma (CCGLC-001)

Hepatocellular Carcinoma Non-resectable

China
Hebei Medical University

Unknown

A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

Gastric Cancer With Positive Exfoliative Cancer Cells
Huazhong University of Science and Technology
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

Gastric Cancer

China
Tang-Du Hospital

Unknown

S-1 Combined Cisplatin HIPEC for Palliative Operation Gastric Cancer of Stage IV Limited Peritoneal Metastasis

Stage IV Gastric Cancer

China
Fudan University
The First Affiliated Hospital of Anhui Medical University; Guangdong Provincial... and other collaborators

Withdrawn

Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.

Gastric Cancer

China
Beijing Friendship Hospital

Unknown

Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer

Gastric Cancer

China
The Affiliated Hospital of Qingdao University

Unknown

PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC

NSCLC Stage IV | PD-1 | ARID1A

China
The Affiliated Hospital of the Chinese Academy...

Unknown

Study of S-1 as Second Line Treatment on Advanced Pancreatic Cancers (APC-S1)

Pancreatic Cancer

China
Fondazione Policlinico Universitario Agostino Gemelli...

Not yet recruiting

Uroial Plus in the Management of Infections and Urinary Symptoms Associated With Ureteral Stents (USSIAL)

Urinary Tract Infections | Ureteral Stent-Related Symptom
Taiho Pharmaceutical Co., Ltd.

Completed

Study of S-1 Plus LV for Untreated Metastatic Colorectal Cancer

Colorectal Cancer

China, Japan
Wuhan Union Hospital, China

Withdrawn

Safety and Efficacy Study of Chemotherapy Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer (XHZL)

Colorectal Cancer | Chemotherapy | Angiogenesis
Peking University Cancer Hospital & Institute

Recruiting

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Unresectable Hepatocellular Carcinoma

China
Shanghai Ninth People's Hospital Affiliated to...

Completed

A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Head and Neck Squamous Cell Carcinoma

China
AIPING ZHOU

Not yet recruiting

SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

Immunotherapy | Sintilimab | Locally Advanced Solid Tumor | Oxaliplatin | HER2-positive | Gastric or Gastroesophageal Junction Adenocarcinoma | S-1

China
Asan Medical Center

Withdrawn

Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML) (IDEAL-E)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Korea, Republic of
Taiho Oncology, Inc.
Quintiles, Inc.; United BioSource, LLC

Completed

Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer

Advanced Non-Small Cell Lung Cancer
Hamamatsu University

Unknown

Pharmacokinetic and Pharmacodynamic Study of S-1 in Patients With Digestive Organ Cancer

Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Colon Cancer

Japan

Search clinical trials for: Apatinib plus S-1

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations